Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing and nucleic acid-based technologies, and Stratum
Reservoir (Isotech), LLC (“Isotech”), a division of Stratum
Reservoir and a leader in laboratory stable isotope analysis, a
technique used for fingerprinting naturally occurring organic
compounds such as cotton, today announced that they have entered
into a Memorandum of Understanding (MoU). Under the terms of the
MoU, Applied DNA will deploy Isotech’s isotopic analysis (IA) as a
confirmatory assay for cotton genotyping, the process through which
cotton DNA is utilized to determine cotton fiber and fabric origin
forensically. The MoU is expected to be followed by a definitive
agreement between the companies.
The signing of the MoU follows the joint presentation of initial
data by the companies at an American Apparel and Footwear
Association event that describes a methodology and findings for the
successful determination of Egyptian cotton fiber, yarn and fabric
origin using cotton genomics with affirmation by IA. The
complementary use of IA to Applied DNA’s CertainT® platform for
textile traceability yields a continuity of forensic data across
the entirety of a natural fiber-based value chain – from source to
finished goods – to ensure adherence to social (avoidance of
products made with forced or slave labor) and environmental
practices (sustainable, organic) aligned with regulatory and
consumer expectations. Per the MoU, the companies will support
business development opportunities for cotton traceability. They
will also continue to build and compile a global database of
cotton, yarn, and fabric samples from known sources to broaden the
application and utility of IA.
MeiLin Wan, vice president of Textile Sales at Applied DNA,
stated, “The use of IA complements our CertainT platform to deliver
what we believe is a best-in-class, multi-layered approach to
supply chain traceability and assurance across the entirety of
natural fiber-based value chains. With CertainT, once origin is
established, we deliver certainty that we believe is immutable and
forensic from source-to-shelf. The power of DNA is now augmented
with IA.”
“Stable isotope analysis is a powerful tool that we have
historically used in the oil and gas industry,” said Steven
Pelphrey, Director of Stratum Reservoir (Isotech), LLC. “Through
our collaboration with Applied DNA, we can now more broadly apply
our proven technology and techniques to the textile industry. This
both enhances Applied DNA’s CertainT platform with an additional
layer of geographic provenance and delivers an unmatched solution
to the marketplace.”
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction (“PCR”)-based manufacturing
platform that allows for the large-scale production of specific DNA
sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a
high-throughput turnkey solution for population-scale COVID-19
testing. safeCircle is designed to look for infection within
defined populations or communities utilizing high throughput
testing methodologies that increase testing efficiencies and
provide for rapid turn-around-times. The Company has also submitted
a request for an EUA-authorization for its LineaTM SARS-CoV-2
Mutation Panel, an assay-based panel for the detection of certain
SARS-CoV-2 genetic mutations.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
About Stratum Reservoir (Isotech), LLC
Isotech is a leading provider of laboratory services and
equipment designed to deliver scientific insights for customers
around the world, including specializing in high-precision carbon,
hydrogen, oxygen, nitrogen and sulfur-isotope analysis for a
variety of industries. Isotech is a member of the Stratum Reservoir
group of companies, which operates rock and fluids analysis
laboratories to enable the discovery and sustainable development of
energy resources through applied geosciences.
For more information, visit www.stratumreservoir.com and follow
us on LinkedIn.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA's future
plans, projections, strategies, and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance,
including Applied DNA's ability to successfully enter into
commercial contracts for the implementation of its CertainT®
platform, the unknown ability to identify and commercialize large
numbers of cotton geographic biomarkers, the uncertainties inherent
in research and development, and various other factors detailed
from time to time in Applied DNA's SEC reports and filings,
including our Annual Report on Form 10-K filed on December 9, 2021,
and other reports we file with the SEC, which are available at
www.sec.gov. Applied DNA undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events, unless otherwise required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211215005459/en/
For Applied DNA: Investors: Sanjay M. Hurry,
917-733-5573, sanjay.hurry@adnas.com Program Manager: MeiLin
Wan, 631-240-8849, meilin.wan@adnas.com Web: www.adnas.com
Twitter: @APDN
For Isotech: Media Inquiries: Jason Buchman, (832)
375-6800, jason.buchman@stratumreservoir.com Program
Manager: Steve Pelphrey, (217) 398-3490,
steven.pelphrey@stratumreservoir.com
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024